Drug interactions in the treatment of depression in patients with ischemic heart disease

Journal of Clinical Psychiatry

Volumn 73, Issue 12, 2012, Pages

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; FLUOXETINE; FLUVOXAMINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; BLEEDING; CASE REPORT; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 84871836267     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12f08248     Document Type: Review

References (26)

1. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry. 1998;155(1):4-11. PubMed (Pubitemid 28037542)
2. Santangelo A, Testaì M, Barbagallo P, et al. Use of specific serotonin reuptake inhibitors (SSRIs) (sertraline or citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: evidence from a Sicilian population > 80 years recovered in the assisted sanitary residences (RSA). Arch Gerontol Geriatr. 2009;48(3):350-352. doi:10.1016/j.archger.208.02.014 PubMed
3. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: Coronary Psychosocial Evaluation Studies randomized controlled trial. Arch Intern Med. 2010;170(7):600-608. doi:10.101/archinternmed.2010.29 PubMed
4. Pizzi C, Rutjes AWS, Costa GM, et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972-979. doi:10.1016/j.amjcard.2010.1.017 PubMed
5. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104(16):1894-1898. doi:10.161/hc4101.097519 PubMed (Pubitemid 32983230)
6. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108(1):32-36. doi:10.161/01.CIR.079172.4329.CD PubMed (Pubitemid 36859016)
7. Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 2004;27(14):1157-1165. doi:10.2165/02018-20427140-06 PubMed (Pubitemid 39647855)
8. Taylor CB, Youngblood ME, Catellier D, et al. ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-798. doi:10.101/archpsyc.62.7.792 PubMed (Pubitemid 41002762)
9. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63(12):1358-1367. doi:10.101/archpsyc.63.12. 1358 PubMed (Pubitemid 44878519)
10. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med. 2007;120(6):525-530. doi:10.1016/j.amjmed.206.10.026 PubMed (Pubitemid 46764624)
11. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119(2):113-116. doi:10.1016/j.amjmed.205.03.04 PubMed (Pubitemid 43151473)
12. Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. doi:10.408/JCP.09r05786blu PubMed
13. Serebruany VL, Glassman AH, Malinin AI, et al, Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108(8):939-944. doi:10.161/01.CIR.085163.21752.0A PubMed (Pubitemid 37048222)
14. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail. 2003;5(4):517-521. doi:10.1016/S138-9842(03)05-9 PubMed (Pubitemid 37021646)
15. Lekakis J, Ikonomidis I, Papoutsi Z, et al. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int J Cardiol. 2010;139(2):150-158. doi:10.1016/j.ijcard.208.10.010 PubMed
16. Pizzi C, Mancini S, Angeloni L, et al. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86(5):527-532. doi:10.1038/clpt.209.121 PubMed
17. Tseng YL, Chiang ML, Huang TF, et al. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res. 2010;126(6):517-523. doi:10.1016/j.thromres.2010.09.017 PubMed
18. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2-8. doi:10.1016/S02-9343(9)0301-0 PubMed (Pubitemid 30058271)
19. Rosenberg LB, Whang W, Shimbo D, et al. Exposure to tricyclic antidepressants is associated with an increased risk of incident CHD events in a population-based study. Int J Cardiol. 2010;145(1):124-125. doi:10.1016/j.ijcard.209.06.036 PubMed
20. Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183(16):1835-1843. doi:10.1503/cmaj.10912 PubMed
21. Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. doi:10.124/dmd.32.8.821 PubMed (Pubitemid 38955611)
22. Fontes-Carvalho R, Albuquerque A, Araújo C, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396-404. doi:10.1097/MEG.0b013e328346010 PubMed
23. Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698-1711. doi:10.124/dmd.12.04575 PubMed
24. Food and Drug Administration. Information on clopidogrel bisulfate (marketed as Plavix). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm. Updated October 27, 2010. Accessed October 31, 2012.
25. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-1830. doi:10.101/jama.2010.1543 PubMed
26. Food and Drug Administration. Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Updated November 17, 2009. Accessed October 31, 2012.